Clinical trial · Observational
Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma: Multicenter Retrospective Analysis
NCT04061850CI-TRIAL-00047812MCLRRcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To review the efficacy and the safety of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression free survival period
- timeFrame
- Up to 3 years, From the date of diagnosis with MCL to the date of relapse/disease progression, or last follow-up date
- description
- Progression free survival period with ibrutinib
Secondary outcomes (1)
- measure
- Overall response rate
- timeFrame
- Up to 3 years, From the date of diagnosis with MCL to the date of death, or last follow-up date
- description
- Overall response rate with ibrutinib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with MCL diagnosed by a pathologist (based on the WHO 2017 classification) 1. mantle cell lymphoma 2. leukemic nonnodal mantle cell lymphoma 3. in situ mantle cell neoplasia * Aged ≥ 19 years * Relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation Exclusion Criteria: * Patients whose clinical and pathological data are not available * Patients who were not treated with ibrutinib
References
Publications (0)
Data not yet available
No reference posted for this study.